Clinical trials: Locally Advanced Non-Small Cell Lung Cancer
Esophageal, Toxicity
MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)
This is a Phase I-II study evaluating the feasibility, safety, and efficacy of swallowed MnSOD plasmid/liposome (PL) transgene given as protection against radiation-induced esophagitis during concurrent paclitaxel and carboplatin…
- Trial name
- MnSOD (NCT00618917)
- Testing
- Manganese Superoxide Dismutase Plasmid Liposome, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Joel Greenberger
Advanced or Metastatic NSCLC
Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC
This is a randomized, controlled, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of oral HS-10504 monotherapy versus platinum-based doublet chemotherapy in participants with locally…
- Trial name
- NCT07754123
- Testing
- HS-10504, platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin)
- Volunteers
- 206 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor, Adult, Head and Neck Cancer
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03543813
- Testing
- CX-2029
- Where
- 25 sites in United States, South Korea and 2 more
- Volunteers
- 133 people
- Sponsor
- CytomX Therapeutics
Nonsmall Cell Lung Cancer
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following…
- Trial name
- NCT02981108
- Testing
- HS-10296
- Where
- 10 sites in United States
- Volunteers
- 364 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
This is a Phase 3, randomized, open-label, comparative, multicenter, international study for NSCLC patients whose tumor tissue exhibits ROS1 fusion positivity (i.e., ROS1+) and who have not previously received an ROS1-targeted…
- Trial name
- NCT06564324
- Testing
- Taletrectinib, Crizotinib
- Where
- 29 sites in China
- Volunteers
- 194 people
- Sponsor
- Nuvation Bio Inc.
Stomatitis
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal…
- Trial name
- TROPION-SWISH (NCT07357597)
- Testing
- Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd)
- Where
- 40 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Neoadjuvant Therapy, Concurrent Chemoradiotherapy
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Consolidative immunotherapy following concurrent chemoradiotherapy, based on the PACIFIC trial, has become the standard treatment for locally advanced non-small cell lung cancer (LANSCLC), leading to a 5-year survival rate of…
- Conditions
- Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy, Locally Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT06734702
- Testing
- Neoadjuvant therapy, Hypo-RT and concurrent chemotherapy, CFRT and concurrent chemotherapy
- Where
- China
- Volunteers
- 497 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer
This phase II trial is to compare neoadjuvant chemotherapy with concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer (NSCLC) to address optimal induction strategy.
- Trial name
- NCT01054482
- Testing
- Pre-operative chemotherapy, Pre-operative concurrent chemoradiation therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Non-small Cell Lung Carcinoma
Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer
The purpose of the present trial is to assess if induction concurrent chemoradiotherapy followed by consolidation chemotherapy will improve survival in comparison with the same chemotherapy given as induction followed by…
- Trial name
- NCT00633568
- Testing
- Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel, Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel
- Where
- 19 sites in Belgium, France and 2 more
- Volunteers
- 125 people
- Sponsor
- European Lung Cancer Working Party
Locally Advanced or Metastatic NSCLC
PBF-1129 in Patients With NSCLC
Phase I clinical trial in Eastern Cooperative Oncology Group (ECOG) 0-1 patients with locally advanced or metastatic NSCLC to evaluate safety and tolerability of the compound PBF-1129, an Adenosine A2b receptor antagonist.
- Trial name
- NCT03274479
- Testing
- PBF-1129
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Palobiofarma SL
Locally Advanced Non-small Cell Lung Cancer
The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer
This study is a prospective cohort study to evaluate the peripheral blood lymphocyte subsets as predicative biomarkers reflecting the efficacy and toxicity in patients with locally advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT06287320
- Testing
- concurrent or sequential chemoradiotherapy, Immunotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-Small-Cell Lung Carcinoma
Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
Primary : To determine the safety profile of each treatment group. Secondary : To determine efficacy in term of overall response, disease free survival and survival at 1 and 2 years.
- Trial name
- NCT00271323
- Testing
- docetaxel and cisplatin, radiotherapy
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer
The purpose of this study is to determine if the use of exploratory immunologic biomarkers, functional MRI images can serve as early predictors for response of NSCLC.
- Trial name
- NCT01899989
- Testing
- Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
This is an open label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, preliminary efficacy of Dositinib in participants of locally advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT07231068
- Testing
- Dositinib mesylate tablets
- Where
- 5 sites in China
- Volunteers
- 153 people
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Lung Cancer, Non-Small Cell
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
This is a phase II, open-label, multicenter, randomized study to evaluate the efficacy and safety of GSK1120212 compared with docetaxel in the second line setting for subjects with locally advanced or metastatic (Stage IV)…
- Trial name
- NCT01362296
- Testing
- GSK1120212, docetaxel
- Where
- 60 sites in United States, France and 6 more
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline